San Mateo, CA – March 27, 2018: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for over-the-counter (OTC) sales of its SmartinhalerTM sensor for AstraZeneca’s Symbicort® aerosol asthma inhaler. The Smartinhaler sensor is a device installed onto a […]
Soap and glory for Irish entrepreneur Deborah Neill We’re always on the lookout for new, innovative, and most importantly helpful products to add to our growing catalogue. A new addition to our site is Deborah Neill Handmade Soap, beautiful handmade soap created a cancer survivor to help soothe irritated skin that has been affected cancer treatment. Here, soapmaker […]
Antibiotic resistance adds more than $1,000 to the cost of treatment for a single patient, according to a new study. Multiply that the estimated number of antibiotic-resistant infections, and costs run well over $2 billion per year. The study, published Wednesday in Health Affairs and conducted researchers from Emory University and Saint Louis University, used data […]
CATEGORY: Featured Tuesday, March 20, 2018 8:00 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into definitive purchase agreements with certain institutional investors to sell in a registered […]
Also Announces that Major Hospital Will Host New Training Center for RECELL in Beijing Valencia, CA, USA, and Melbourne, Australia, 19 March 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced the commencement of a randomized, controlled clinical trial of RECELL® in the treatment of deep partial-thickness (second-degree) burns in China. RECELL is a medical […]
CATEGORY: Featured Monday, March 19, 2018 4:10 pm EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “The promising clinical results I have observed to-date support the potential of bacteriophage therapeutics to be a safe and potent adjunct treatment for serious bacterial infections.” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company […]
Posted on 15/03/2018 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) […]
Announced positive topline results for the first seven patients treated with AB-SA01 or AB-PA01 under ongoing expanded access program. Treatment was well tolerated with 86% of patients achieving treatment success Signed a Cooperative Research and Development Agreement with the U.S. Department of Veterans Affairs Completed a public offering of common stock in Jan. 2018 for […]
CATEGORY: Featured Tuesday, March 13, 2018 6:50 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “We are delighted to collaborate with the U.S. Department of Veterans Affairs on the compassionate use of AB-SA01 and AB-PA01 within the VA Palo Alto Health Care System” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage […]
12 Mar 2018 SAN MATEO, Calif., March 12, 2018 (GLOBE NEWSWIRE) — Adherium (ASX:ADR), a digital health company that improves medication adherence and patient outcomes, today announced that members of its Board of Directors recently purchased approximately 1.4 million shares on the open market. The timing of these purchases complied with the Company’s “blackout period” […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: